Brooks Laboratories

Brooks Laboratories OCF Margin

The Operating Cash Flow Margin of Brooks Laboratories (BROOKS.NS) as of Oct 16, 2026 is 10.02 %. In the previous year, Operating Cash Flow Margin was 2.13 % — a change of 369.47% (higher).

OCF Margin

10.02 %

YoY

369.47%

Last updated:

Operating Cash Flow Margin of Brooks Laboratories is 2026 10.02 % . Operating Cash Flow Margin of Brooks Laboratories was 2025 2.13 % . It decreases by 369.47% higher compared to the previous year.

The Brooks Laboratories OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2019
-9.18 INR
Jan 1, 2020
-13.58 INR
Jan 1, 2021
5.79 INR
Jan 1, 2022
-41.06 INR
Jan 1, 2023
-23.19 INR
Jan 1, 2024
-12.18 INR
Jan 1, 2025
2.13 INR
Jan 1, 2026
10.02 INR
The Brooks Laboratories OCF Margin history
YEAROCF MarginYoY
10.02 %+369.47%
2.13 %-117.53%
-12.18 %-47.49%
-23.19 %-43.52%
-41.06 %-809.72%
5.79 %-142.60%
-13.58 %+48.00%
-9.18 %-17.30%
-11.10 %-166.49%
16.69 %+64.44%
10.15 %+306.11%
2.50 %-81.79%
13.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Brooks Laboratories Stock analysis

What does Brooks Laboratories do? Brooks Laboratories Ltd is a pharmaceutical manufacturing enterprise headquartered in Mumbai, Maharashtra, India, operating within the health care sector under the industry classification of life sciences tools and services. The company maintains a workforce of 296 full-time employees dedicated to its research and development initiatives and production operations. Brooks Laboratories went public on September 2, 2011, listing its shares on the National Stock Exchange of India under the ticker symbol BROOKS.NS and the ISIN INE650L01011. The firm’s primary business activity revolves around the Pharmaceuticals segment, where it focuses on the manufacturing of a diverse range of pharmaceutical dosage forms. These products include injections, tablets, dry syrups, and eye and ear drops, catering to various therapeutic needs. A significant portion of the company’s portfolio consists of products under the Carbapenem category, which includes several specific formulations such as Imipenem combined with Cilastatin in 250mg and 500mg strengths, as well as Meropenem in dosages ranging from 125mg to 1000mg. The Meropenem offerings also include combinations with Sulbactam and Tazobactam, alongside Doripenem in 500mg and 1000mg strengths. In addition to Carbapenems, Brooks Laboratories produces Penicillins available in injection, tablet, and dry syrup forms. The General category of its product line encompasses liquid injections, dry powder injections, and ophthalmic and otic drops. Notable liquid injections include Iron sucrose with a concentration of 100mg/5ml. The company’s manufacturing infrastructure includes plants located in Baddi, Himachal Pradesh. Brooks Laboratories markets its pharmaceutical products both nationally and internationally, supplying to various regulated markets around the world. The company’s operational scope is defined by its commitment to producing high-quality pharmaceuticals that meet international regulatory standards. Through its dedicated team and established manufacturing facilities, Brooks Laboratories continues to serve the global health care market with its extensive range of medicinal products. The firm’s online presence is maintained through its official website, providing further information on its products and services. As a listed entity, the company is subject to the regulatory requirements of the Indian stock markets, ensuring transparency and accountability in its corporate governance and financial reporting. Brooks Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Brooks Laboratories stock

Operating Cash Flow Margin of Brooks Laboratories is 10.02 % in 2026.

Operating Cash Flow Margin of Brooks Laboratories changed from 2.13 % to 10.02 %, representing a 369.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Brooks Laboratories since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Brooks Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Brooks Laboratories

All Key Metrics — Brooks Laboratories